IceCure Medical Ltd (NASDAQ:ICCM - Free Report) - Analysts at Brookline Capital Management decreased their FY2027 earnings per share (EPS) estimates for shares of IceCure Medical in a research report issued on Thursday, March 27th. Brookline Capital Management analyst K. Dolliver now anticipates that the company will post earnings per share of $0.22 for the year, down from their prior estimate of $0.23. The consensus estimate for IceCure Medical's current full-year earnings is ($0.28) per share. Brookline Capital Management also issued estimates for IceCure Medical's FY2028 earnings at $0.32 EPS and FY2029 earnings at $0.42 EPS.
Separately, HC Wainwright reaffirmed a "buy" rating and set a $2.50 price objective on shares of IceCure Medical in a research report on Friday, March 28th.
Check Out Our Latest Stock Report on IceCure Medical
IceCure Medical Trading Down 0.8 %
Shares of NASDAQ ICCM traded down $0.01 during midday trading on Monday, hitting $1.23. 138,773 shares of the company traded hands, compared to its average volume of 519,003. IceCure Medical has a 12-month low of $0.48 and a 12-month high of $1.66. The firm has a market cap of $68.27 million, a P/E ratio of -4.24 and a beta of 0.37. The stock has a 50-day moving average price of $1.32 and a 200 day moving average price of $1.00. The company has a debt-to-equity ratio of 0.02, a quick ratio of 2.27 and a current ratio of 2.67.
IceCure Medical (NASDAQ:ICCM - Get Free Report) last released its quarterly earnings results on Thursday, March 27th. The company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.01). IceCure Medical had a negative net margin of 376.85% and a negative return on equity of 124.44%. The company had revenue of $1.07 million during the quarter, compared to the consensus estimate of $1.07 million.
Hedge Funds Weigh In On IceCure Medical
An institutional investor recently raised its position in IceCure Medical stock. XTX Topco Ltd increased its holdings in IceCure Medical Ltd (NASDAQ:ICCM - Free Report) by 123.7% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 58,866 shares of the company's stock after acquiring an additional 32,555 shares during the quarter. XTX Topco Ltd owned about 0.11% of IceCure Medical worth $65,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 0.62% of the company's stock.
IceCure Medical Company Profile
(
Get Free Report)
IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.
See Also
Before you consider IceCure Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IceCure Medical wasn't on the list.
While IceCure Medical currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
